Barbara Seliger
| Titel: | Prof. med. habil. Dr. rer. nat. |
| Denomination: | Professur für Translationale Immunologie kardiovaskulärer Erkrankungen (FGW) |
| Aktuelle Position: | Direktorin des Institut für Translationale Immunologie |
| Adresse: |
Campus Brandenburg an der Havel
Gertrud-Piter-Platz 7
Hoftür links, 1. Geschoss
14770 Brandenburg an der Havel
|
| Telefon: | +49 3381 21-82216 (Sekretariat Frau Wolf) |
| E-Mail: | barbara.seliger@mhb-fontane.de |
| An der MHB seit: | 01.10.2022 |
| Forschung: | Tumorimmunologie, Immuntherapie, Infektionsimmunologie |
| Lehrschwerpunkt(e): | Tumorimmunologie, Immuntherapie, Infektionsimmunologie |
Zitat
Wissen, dass man nichts weiß, ist das Allerhöchste. (Laotse)Publikationen
Meine besten 5 Publikationen:
1. Vaxevanis CK, Friedrich M, Tretbar SU, Handke D, Wang Y, Blümke J, Dummer R, Massa C, Seliger B. Identification and characterization of novel CD274 (PD-L1) regulating microRNAs and their functional relevance in melanoma. Clin Transl Med. 2022 Jul;12(7):e934. doi: 10.1002/ctm2.934. Identification and characterization of novel CD274 (PD-L1) regulating microRNAs and their functional relevance in melanoma - PubMed (nih.gov)
2. Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, Jackisch C, van Mackelenbergh M,Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Weber K., Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC . 2020 Nov;8(2):e001261. doi: 10.1136/jitc-2020-001261. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC - PubMed (nih.gov)
3. Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A, Aranda F, Durand S, Boissonnas A, Fucikova J, Senovilla L, Enot D, Hensler M, Kremer M, Stoll G, Hu Y, Massa C, Formenti SC, Seliger B, Elemento O, Spisek R, André F, Zitvogel L, Delaloge S, Kroemer G, Galluzzi L. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nat Commun. 2020 Jul 30;11(1):3819. doi: 10.1038/s41467-020-17644-0. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer - PubMed (nih.gov)
4. Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O. NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity. 2018 Jan 16;48(1):107-119.e4. NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis - PubMed (nih.gov)
5. Zhou F, Liu Y, Rohde C, Pauli C, Pabst C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar M, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel W, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hüttelmaier S, Müller-Tidow C. AML1-ETO requires enhanced C/D box snoRNA formation to induce self-renewal and leukemia. Nature Cell Biol. 2017; 19(7):844-855. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia - PubMed (nih.gov)
